Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. J Clin Oncol. 2024 Apr 20; 42(12):1403-1414.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Carcinoma, Transitional Cell
Cisplatin
Humans
Pain
Patient Reported Outcome Measures
Quality of Life
Sleep Initiation and Maintenance Disorders

authors with profiles

Peter H. O'Donnell